Faculty

Back to Index
Parkash Singh Gill, MD
Professor of Medicine
Renette and Marshall Ezralow Family Chair in Cancer Therapeutics
Medicine
NOR 6332 Health Sciences Campus Los Angeles
+1 323 865 3909

Overview

Dr. Gill's primary research interest is in studying novel targets that are expressed both in tumor blood vessels as well as the tumor cell. He has demonstrated the ability to identify and validate novel targets, develop novel target therapeutics and collaborate with clinical investigators to conduct early stage clinical trials.

Dr. Gill has a strong history of clinical investigations and drug development. His clinical investigations led to the approval of three cancer drugs by the FDA. He also served on the advisory panel for the FDA advisory committee on biologics. Over the past several years his work has focused on the identification of novel cancer and cancer blood vessel targets, validation of the targets in various model systems including genetic mouse models.

Publications

Liang M, Adisetiyo H, Li X, Liu R, Gill P, Roy-Burman P, Jones JO, Mulholland DJ. Correction: Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model. PLoS One. 2016; 11(3):e0152243. View in: PubMed

Zhou B, Wang H, Liu R, Wang M, Deng H, Giglio BC, Gill PS, Shan H, Li Z. PET Imaging of Dll4 Expression in Glioblastoma and Colorectal Cancer Xenografts Using (64)Cu-Labeled Monoclonal Antibody 61B. Mol Pharm. 2015 Oct 5; 12(10):3527-34. View in: PubMed

Wang H, Li D, Liu S, Liu R, Yuan H, Krasnoperov V, Shan H, Conti PS, Gill PS, Li Z. Small-Animal PET Imaging of Pancreatic Cancer Xenografts Using a 64Cu-Labeled Monoclonal Antibody, MAb159. J Nucl Med. 2015 Jun; 56(6):908-13. View in: PubMed

Pan CX, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, Ghosh PM, Gill P, Airhart S, Bult C, Gandara DR, Liu E, de Vere White RW. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. PLoS One. 2015; 10(8):e0134346. View in: PubMed

Liang M, Adisetiyo H, Liu X, Liu R, Gill P, Roy-Burman P, Jones JO, Mulholland DJ. Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model. PLoS One. 2015; 10(7):e0131232. View in: PubMed

Ferguson BD, Carol Tan YH, Kanteti RS, Liu R, Gayed MJ, Vokes EE, Ferguson MK, John Iafrate A, Gill PS, Salgia R. Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. Sci Rep. 2015; 5:10641. View in: PubMed

Ferguson BD, Tretiakova MS, Lingen MW, Gill PS, Salgia R. Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies - implications for solid tumors and potential for therapeutic inhibition. Growth Factors. 2014 Dec; 32(6):202-6. View in: PubMed

Liu S, Li D, Guo J, Canale N, Li X, Liu R, Krasnoperov V, Gill PS, Conti PS, Shan H, Li Z. Design, Synthesis, and Validation of Axl-Targeted Monoclonal Antibody Probe for microPET Imaging in Human Lung Cancer Xenograft. Mol Pharm. 2014 Nov 3; 11(11):3974-9. View in: PubMed

Li D, Liu S, Liu R, Park R, Yu H, Krasnoperov V, Gill PS, Li Z, Shan H, Conti PS. Axl-Targeted Cancer Imaging with Humanized Antibody h173. Mol Imaging Biol. 2014 Aug; 16(4):511-8. View in: PubMed

Li X, Choi WW, Yan R, Yu H, Krasnoperov V, Kumar SR, Schuckman A, Klumpp DJ, Pan CX, Quinn D, Gill IS, Gill PS, Liu R. The Differential Expression of EphB2 and EphB4 Receptor Kinases in Normal Bladder and in Transitional Cell Carcinoma of the Bladder. PLoS One. 2014; 9(8):e105326. View in: PubMed

Liu R, Li X, Gao W, Zhou Y, Wey S, Mitra SK, Krasnoperov V, Dong D, Liu S, Li D, Zhu G, Louie S, Conti PS, Li Z, Lee AS, Gill PS. Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing PI3K/AKT Signaling, Tumor Growth, and Metastasis. Clin Cancer Res. 2013 Dec 15; 19(24):6802-11. View in: PubMed

Li D, Liu S, Liu R, Zhou Y, Park R, Naga K, Krasnoperov V, Gill PS, Li Z, Shan H, Conti PS. EphB4-Targeted Imaging with Antibody h131, h131-F(ab')2 and h131-Fab. Mol Pharm. 2013 Dec 2; 10(12):4527-33. View in: PubMed

Liu S, Li D, Park R, Liu R, Xia Z, Guo J, Krasnoperov V, Gill PS, Li Z, Shan H, Conti PS. PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies. J Nucl Med. 2013 Jul; 54(7):1094-100. View in: PubMed

Li D, Liu S, Liu R, Park R, Hughes L, Krasnoperov V, Gill PS, Li Z, Shan H, Conti PS. Targeting the EphB4 receptor for cancer diagnosis and therapy monitoring. Mol Pharm. 2013 Jan 7; 10(1):329-36. View in: PubMed

Hasina R, Mollberg N, Kawada I, Mutreja K, Kanade G, Yala S, Surati M, Liu R, Li X, Zhou Y, Ferguson BD, Nallasura V, Cohen KS, Hyjek E, Mueller J, Kanteti R, El Hashani E, Kane D, Shimada Y, Lingen MW, Husain AN, Posner MC, Waxman I, Villaflor VM, Ferguson MK, Varticovski L, Vokes EE, Gill P, Salgia R. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res. 2013 Jan 1; 73(1):184-94. View in: PubMed

Ferguson BD, Liu R, Rolle CE, Tan YH, Krasnoperov V, Kanteti R, Tretiakova MS, Cervantes GM, Hasina R, Hseu RD, Iafrate AJ, Karrison T, Ferguson MK, Husain AN, Faoro L, Vokes EE, Gill PS, Salgia R. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. PLoS One. 2013; 8(7):e67668. View in: PubMed

Liu R, Ferguson BD, Zhou Y, Naga K, Salgia R, Gill PS, Krasnoperov V. EphB4 as a therapeutic target in mesothelioma. BMC Cancer. 2013; 13:269. View in: PubMed

He M, Zhang W, Bakken T, Schutten M, Toth Z, Jung JU, Gill P, Cannon M, Gao SJ. Cancer Angiogenesis Induced by Kaposi Sarcoma-Associated Herpesvirus Is Mediated by EZH2. Cancer Res. 2012 Jul 15; 72(14):3582-92. View in: PubMed

Shi S, Liu J, Joshi SB, Krasnoperov V, Gill P, Middaugh CR, Volkin DB. Biophysical characterization and stabilization of the recombinant albumin fusion protein sEphB4-HSA. J Pharm Sci. 2012 Jun; 101(6):1969-84. View in: PubMed

Liu R, Trindade A, Sun Z, Kumar R, Weaver FA, Krasnoperov V, Naga K, Duarte A, Gill PS. Inhibition of Notch signaling by Dll4-Fc promotes reperfusion of acutely ischemic tissues. Biochem Biophys Res Commun. 2012 Feb 3; 418(1):173-9. View in: PubMed

Trindade A, Djokovic D, Gigante J, Badenes M, Pedrosa AR, Fernandes AC, Lopes-da-Costa L, Krasnoperov V, Liu R, Gill PS, Duarte A. Low-dosage inhibition of dll4 signaling promotes wound healing by inducing functional neo-angiogenesis. PLoS One. 2012; 7(1):e29863. View in: PubMed

Brar M, Cheng L, Yuson R, Mojana F, Freeman WR, Gill PS. Ocular safety profile and intraocular pharmacokinetics of an antagonist of EphB4/EphrinB2 signalling. Br J Ophthalmol. 2010 Dec; 94(12):1668-73. View in: PubMed

Ahmad A, Groshong JS, Matta H, Schamus S, Punj V, Robinson LJ, Gill PS, Chaudhary PM. Kaposi sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 cooperates with Myc to promote lymphoma in mice. Cancer Biol Ther. 2010 Nov; 10(10):1033-40. View in: PubMed

Lee HR, Lee S, Chaudhary PM, Gill P, Jung JU. Immune evasion by Kaposi's sarcoma-associated herpesvirus. Future Microbiol. 2010 Sep; 5(9):1349-65. View in: PubMed

Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther. 2010 Aug; 9(8):2377-88. View in: PubMed

Liu R, Gong M, Li X, Zhou Y, Gao W, Tulpule A, Chaudhary PM, Jung J, Gill PS. Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma. Blood. 2010 Jul 15; 116(2):297-305. View in: PubMed

Zhang Y, Liu R, Ni M, Gill P, Lee AS. Cell surface relocalization of the endoplasmic reticulum chaperone and unfolded protein response regulator GRP78/BiP. J Biol Chem. 2010 May 14; 285(20):15065-75. View in: PubMed

Krasnoperov V, Kumar SR, Ley E, Li X, Scehnet J, Liu R, Zozulya S, Gill PS. Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth. Am J Pathol. 2010 Apr; 176(4):2029-38. View in: PubMed

Liu R, Li X, Tulpule A, Zhou Y, Scehnet JS, Zhang S, Lee JS, Chaudhary PM, Jung J, Gill PS. KSHV-induced notch components render endothelial and mural cell characteristics and cell survival. Blood. 2010 Jan 28; 115(4):887-95. View in: PubMed

He S, Kumar SR, Zhou P, Krasnoperov V, Ryan SJ, Gill PS, Hinton DR. Soluble EphB4 inhibition of PDGF-induced RPE migration in vitro. Invest Ophthalmol Vis Sci. 2010 Jan; 51(1):543-52. View in: PubMed

Djokovic D, Trindade A, Gigante J, Badenes M, Silva L, Liu R, Li X, Gong M, Krasnoperov V, Gill PS, Duarte A. Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis. BMC Cancer. 2010; 10:641. View in: PubMed

Kumar SR, Scehnet JS, Ley EJ, Singh J, Krasnoperov V, Liu R, Manchanda PK, Ladner RD, Hawes D, Weaver FA, Beart RW, Singh G, Nguyen C, Kahn M, Gill PS. Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Res. 2009 May 1; 69(9):3736-45. View in: PubMed

Scehnet JS, Ley EJ, Krasnoperov V, Liu R, Manchanda PK, Sjoberg E, Kostecke AP, Gupta S, Kumar SR, Gill PS. The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood. 2009 Jan 1; 113(1):254-63. View in: PubMed

Trindade A, Kumar SR, Scehnet JS, Lopes-da-Costa L, Becker J, Jiang W, Liu R, Gill PS, Duarte A. Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos. Blood. 2008 Sep 1; 112(5):1720-9. View in: PubMed

Yavrouian EJ, Sinha UK, Rice DH, Salam MT, Gill PS, Masood R. The significance of EphB4 and EphrinB2 expression and survival in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2008 Sep; 134(9):985-91. View in: PubMed

Cozen W, Gill PS, Salam MT, Nieters A, Masood R, Cockburn MG, Gauderman WJ, Martínez-Maza O, Nathwani BN, Pike MC, Van Den Berg DJ, Hamilton AS, Deapen DM, Mack TM. Interleukin-2, interleukin-12, and interferon-gamma levels and risk of young adult Hodgkin lymphoma. Blood. 2008 Apr 1; 111(7):3377-82. View in: PubMed

Benedito R, Trindade A, Hirashima M, Henrique D, da Costa LL, Rossant J, Gill PS, Duarte A. Loss of Notch signalling induced by Dll4 causes arterial calibre reduction by increasing endothelial cell response to angiogenic stimuli. BMC Dev Biol. 2008; 8:117. View in: PubMed

Gill PS. The origin of Kaposi sarcoma. J Natl Cancer Inst. 2007 Jul 18; 99(14):1063. View in: PubMed

Bishop KA, Stantchev TS, Hickey AC, Khetawat D, Bossart KN, Krasnoperov V, Gill P, Feng YR, Wang L, Eaton BT, Wang LF, Broder CC. Identification of Hendra virus G glycoprotein residues that are critical for receptor binding. J Virol. 2007 Jun; 81(11):5893-901. View in: PubMed

Scehnet JS, Jiang W, Kumar SR, Krasnoperov V, Trindade A, Benedito R, Djokovic D, Borges C, Ley EJ, Duarte A, Gill PS. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood. 2007 Jun 1; 109(11):4753-60. View in: PubMed

Ku TK, Nguyen DC, Karaman M, Gill P, Hacia JG, Crowe DL. Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer. Mol Cancer Res. 2007 Apr; 5(4):351-62. View in: PubMed

Damschroder MM, Widjaja L, Gill PS, Krasnoperov V, Jiang W, Dall'Acqua WF, Wu H. Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties. Mol Immunol. 2007 Apr; 44(11):3049-60. View in: PubMed

Sinha UK, Mazhar K, Chinn SB, Dhillon VK, Liu L, Masood R, Rice DH, Gill PS. The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2006 Oct; 132(10):1053-9. View in: PubMed

Masood R, Kumar SR, Sinha UK, Crowe DL, Krasnoperov V, Reddy RK, Zozulya S, Singh J, Xia G, Broek D, Schönthal AH, Gill PS. EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. Int J Cancer. 2006 Sep 15; 119(6):1236-48. View in: PubMed

Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, Scehnet J, Kumar NG, Hawes D, Press MF, Weaver FA, Gill PS. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol. 2006 Jul; 169(1):279-93. View in: PubMed

Levine AM, Tulpule A, Quinn DI, Gorospe G, Smith DL, Hornor L, Boswell WD, Espina BM, Groshen SG, Masood R, Gill PS. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol. 2006 Apr 10; 24(11):1712-9. View in: PubMed

Xia G, Kumar SR, Hawes D, Cai J, Hassanieh L, Groshen S, Zhu S, Masood R, Quinn DI, Broek D, Stein JP, Gill PS. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol. 2006 Apr; 175(4):1245-52. View in: PubMed

Kertesz N, Krasnoperov V, Reddy R, Leshanski L, Kumar SR, Zozulya S, Gill PS. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood. 2006 Mar 15; 107(6):2330-8. View in: PubMed

He S, Ding Y, Zhou J, Krasnoperov V, Zozulya S, Kumar SR, Ryan SJ, Gill PS, Hinton DR. Soluble EphB4 regulates choroidal endothelial cell function and inhibits laser-induced choroidal neovascularization. Invest Ophthalmol Vis Sci. 2005 Dec; 46(12):4772-9. View in: PubMed

Xia G, Kumar SR, Masood R, Koss M, Templeman C, Quinn D, Zhu S, Reddy R, Krasnoperov V, Gill PS. Up-regulation of EphB4 in mesothelioma and its biological significance. Clin Cancer Res. 2005 Jun 15; 11(12):4305-15. View in: PubMed

Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn DI, Henshall SM, Sutherland RL, Pinski JK, Daneshmand S, Buscarini M, Stein JP, Zhong C, Broek D, Roy-Burman P, Gill PS. EphB4 expression and biological significance in prostate cancer. Cancer Res. 2005 Jun 1; 65(11):4623-32. View in: PubMed

Buscarini M, Quek ML, Gill P, Xia G, Quinn DI, Stein JP. Molecular prognostic factors in bladder cancer. BJU Int. 2005 Apr; 95(6):739-42. View in: PubMed

Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S, Gill P. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol. 2005 Feb 10; 23(5):990-8. View in: PubMed

Masood R, Xia G, Smith DL, Scalia P, Still JG, Tulpule A, Gill PS. Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium. Blood. 2005 Feb 1; 105(3):1310-8. View in: PubMed

Hotz HG, Hines OJ, Masood R, Hotz B, Foitzik T, Buhr HJ, Gill PS, Reber HA. VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. Surgery. 2005 Feb; 137(2):192-9. View in: PubMed

Cozen W, Diaz-Sanchez D, James Gauderman W, Zadnick J, Cockburn MG, Gill PS, Masood R, Hamilton AS, Jyrala M, Mack TM. Th1 and Th2 cytokines and IgE levels in identical twins with varying levels of cigarette consumption. J Clin Immunol. 2004 Nov; 24(6):617-22. View in: PubMed

Frankel AE, Gill PS. VEGF and myeloid leukemias. Leuk Res. 2004 Jul; 28(7):675-7. View in: PubMed

Wang JF, Liu ZY, Anand AR, Zhang X, Brown LF, Dezube BJ, Gill P, Ganju RK. Alpha-chemokine-mediated signal transduction in human Kaposi's sarcoma spindle cells. Biochim Biophys Acta. 2004 May 3; 1691(2-3):129-39. View in: PubMed

Cozen W, Gill PS, Ingles SA, Masood R, Martínez-Maza O, Cockburn MG, Gauderman WJ, Pike MC, Bernstein L, Nathwani BN, Salam MT, Danley KL, Wang W, Gage J, Gundell-Miller S, Mack TM. IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood. 2004 Apr 15; 103(8):3216-21. View in: PubMed

Sinha UK, Kundra A, Scalia P, Smith DL, Parsa B, Masood R, Gill PS. Expression of EphB4 in head and neck squamous cell carcinoma. Ear Nose Throat J. 2003 Nov; 82(11):866, 869-70, 887. View in: PubMed

Smith DL, Cai J, Zhu S, Wei W, Fukumoto J, Sharma S, Masood R, Gill PS. Natural killer cell cytolytic activity is necessary for in vivo antitumor activity of the dipeptide L-glutamyl-L-tryptophan. Int J Cancer. 2003 Sep 10; 106(4):528-33. View in: PubMed

Masood R, Kundra A, Zhu S, Xia G, Scalia P, Smith DL, Gill PS. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer. 2003 May 1; 104(5):603-10. View in: PubMed

Bernstein ZP, Chanan-Khan A, Miller KC, Northfelt DW, Lopez-Berestein G, Gill PS. A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Cancer. 2002 Dec 15; 95(12):2555-61. View in: PubMed

Tulpule A, Groopman J, Saville MW, Harrington W, Friedman-Kien A, Espina BM, Garces C, Mantelle L, Mettinger K, Scadden DT, Gill PS. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer. 2002 Jul 1; 95(1):147-54. View in: PubMed

Hotz HG, Gill PS, Masood R, Hotz B, Buhr HJ, Foitzik T, Hines OJ, Reber HA. Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer. J Gastrointest Surg. 2002 Mar-Apr; 6(2):159-66; discussion 166. View in: PubMed

Tulpule A, Sherrod A, Dharmapala D, Young LL, Espina BM, Sanchez MN, Gill PS, Levine AM. Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. Leuk Res. 2002 Feb; 26(2):121-7. View in: PubMed

Masood R, Cesarman E, Smith DL, Gill PS, Flore O. Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor. Am J Pathol. 2002 Jan; 160(1):23-9. View in: PubMed

Powered bySC CTSI